Whether improved glucose control with hybrid closed-loop therapy can preserve C-peptide secretion as compared with standard insulin therapy in persons with new-onset type 1 diabetes is unclear. A ...
This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and Medicaid Services (CMS) criteria for insulin pump coverage. SAN ...
Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...
For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport ...
New research (the Ver-A-T1D trial) presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15–19 September) shows that slow-release (SR) verapamil (360mg ...
Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels This sub-analysis is the first study to evaluate ...
Tandem Diabetes Care® (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the publication of a study, "Adults with Type 2 Diabetes Benefit from Automated Insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results